elranatamab will raise the level or impact of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Elranatamab causes cytokine launch syndrome (CRS) that could suppress activity of CYP enzymes, causing increased exposure of CYP substrates.Even as the US worked with China to crack down on just one fentany